臨床婦人科産科61巻10号

2007年10月発行

今月の臨床 ここまできた分子標的治療

分子標的治療の臨床応用

4．乳癌

著者： 坂本康寛¹ 石岡千加史¹

所属機関： ¹東北大学加齢医学研究所癌化学療法研究分野

ページ範囲：P.1270 - P.1275

文献概要

はじめに
　乳癌は固形癌のなかで薬物療法に対する感受性が最も高い腫瘍の1つであり，内分泌療法薬および化学療法薬に対する標準治療が早くから確立していた．乳癌は分子標的治療薬に対する感受性も高く，HER2陽性転移性乳癌に対するtrastuzumabが固形癌に対する初めての分子標的治療薬として承認された．Trastuzumabの有効性はHER2陽性乳癌の補助療法においても示されたほか，その後，複数の分子標的治療薬が登場し，転移性乳癌に対して有効性が示されている．本稿では，乳癌に対する最新の分子標的治療薬の臨床試験成績についてtrastuzumab，bevacizumab，lapatinib，sunitinib，TSU─68に焦点を絞り概説する．

参考文献

1）Cobleigh MA, Vogel CL, Tripathy D, et al : Multinational study of the efficacy and safety of humanized anti─HER2 monoclonal antibody in women who have HER2─overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 : 2639─2648, 1999

2）Vogel CL, Cobleigh MA, Tripathy D, et al : Efficacy and safety of trastuzumab as a single agent in first─line treatment of HER2─overexpressing metastatic breast cancer. J Clin Oncol 20 : 719─726, 2002

3）Slamon DJ, Leyland─Jones B, Shak S, et al : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 : 783─792, 2001

4）Gasparini G, Gion M, Mariani L, et al : Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first─line therapy of patients with Her─2 positive advanced breast cancer. Breast Cancer Res Treat 101 : 355─365, 2007

5）Marty M, Cognetti F, Maraninchi D, et al : Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2─positive metastatic breast cancer administered as first─line treatment : the M77001 study group. J Clin Oncol 23 : 4265─4274, 2005

6）Xu L, Song S, Zhu J, et al : Capecitabine（X）＋trastuzumab（H）as first─line treatment in patients（pts）with HER2─positive metastatic breast cancer（MBC）: Phase II trial results. Breast Cancer Res Treat 100 : Suppl 1 Abstr2065, 2006

7）Chan A, Martin M, Untch M, et al : Vinorelbine plus trastuzumab combination as first─line therapy for HER 2─positive metastatic breast cancer patients : an international Phase II trial. Br J Cancer 95 : 788─793, 2006

8）Romond EH, Perez EA, Bryant J, et al : Trastuzumab plus adjuvant chemotherapy for operable HER2─positive breast cancer. N Engl J Med 353 : 1673─1684, 2005

9）Smith I, Procter M, Gelber RD, et al : 2─year follow─up of trastuzumab after adjuvant chemotherapy in HER2─positive breast cancer : a random ised controlled trial. Lancet 369 : 29─36, 2007

10）Slamon D, Eiermann W, Robert N, et al : BCIRG 006 : 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel（ACT）with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab（ACTH）with docetaxel, carboplatin and trastuzumab（TCH）in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006, Abstr52

11）Buzdar AU, Valero V, Ibrahim NK, et al : Neoadjuvant therapy with paclitaxel followed by 5─fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2─positive operable breast cancer : an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13 : 228─233, 2007

12）Cobleigh MA, Langmuir VK, Sledge GW, et al : A Phase I／II dose─escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30（5 Suppl 16）: 117─124, 2003

13）Miller KD, Chap LI, Holmes FA, et al : Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 : 792─799, 2005

14）Miller KD, Wang M, Gralow J, et al : A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first─line therapy for locally recurrent or metastatic breast cancer : a trial coordinated by the Eastern Cooperative Oncology Group（E2100）．Breast Cancer Res Treat 94 : Suppl 1 Abstr 3, 2005

15）Miller K, Gradishar W, Moisa C, et al : Capecitabine plus bevacizumab in first line metastatic breast cancer : an interim safety and efficacy report of the first phase of xeloda plus avastin 1st line metastatic breast cancer trial. B Breast Cancer Res Treat 100 : Suppl 1Abstr 2068, 2006

16）Perez EA, Hillman DW, Kugler JW, et al : North Central cancer treatment group（NCCTG）N0432 : Phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 100 : Suppl 1 Abstr 2069, 2006

17）Overmoyer B, Silverman P, Leeming R, et al : Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treat 88 : Suppl 1 Abstr 2088, 2004

18）Wedam SB, Low JA, Yang SX, et al : Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 : 769─777, 2006

19）Geyer CE, Forster J, Lindquist D, et al : Lapatinib plus capecitabine for HER2─positive advanced breast cancer. N Engl J Med 355 : 2733─2743, 2006

20）Iwata H, Toi M, Fujiwara Y, et al : Phase II clinical study of lapatinib（GW572016）in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 100 : Suppl 1 Abstr 1091, 2006

21）Miller KD, Burstein HJ, Elias AD, et al : Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor（TKI），in patients（pts）with previously treated metastatic breast cancer（MBC）．ASCO Annual Meeting : Abstr 563, 2005

22）Saeki T, Aogi K, Toi M : Adding TSU─68 to docetaxel can be effective in patients with anthracycline resistant metastatic breast cancer : the results of two Phase II studies of TSU─68 alone or plus docetaxel. Breast Cancer Res Treat 100 : Suppl 1 Abstr 1105, 2006